MGX
Price
$1.67
Change
+$0.02 (+1.21%)
Updated
May 22 closing price
Capitalization
62.43M
82 days until earnings call
VERV
Price
$4.23
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
390.45M
76 days until earnings call
Interact to see
Advertisement

MGX vs VERV

Header iconMGX vs VERV Comparison
Open Charts MGX vs VERVBanner chart's image
Metagenomi
Price$1.67
Change+$0.02 (+1.21%)
Volume$171.12K
Capitalization62.43M
Verve Therapeutics
Price$4.23
Change-$0.00 (-0.00%)
Volume$4.63K
Capitalization390.45M
MGX vs VERV Comparison Chart
Loading...
MGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MGX vs. VERV commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGX is a StrongBuy and VERV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (MGX: $1.67 vs. VERV: $4.23)
Brand notoriety: MGX and VERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MGX: 45% vs. VERV: 0%
Market capitalization -- MGX: $62.43M vs. VERV: $390.45M
MGX [@Biotechnology] is valued at $62.43M. VERV’s [@Biotechnology] market capitalization is $390.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $111.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MGX’s FA Score shows that 1 FA rating(s) are green whileVERV’s FA Score has 1 green FA rating(s).

  • MGX’s FA Score: 1 green, 4 red.
  • VERV’s FA Score: 1 green, 4 red.
According to our system of comparison, both MGX and VERV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MGX’s TA Score shows that 6 TA indicator(s) are bullish while VERV’s TA Score has 2 bullish TA indicator(s).

  • MGX’s TA Score: 6 bullish, 3 bearish.
  • VERV’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, MGX is a better buy in the short-term than VERV.

Price Growth

MGX (@Biotechnology) experienced а +7.05% price change this week, while VERV (@Biotechnology) price change was -2.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.00%. For the same industry, the average monthly price growth was +5.57%, and the average quarterly price growth was -1.69%.

Reported Earning Dates

MGX is expected to report earnings on Aug 13, 2025.

VERV is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+3.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VERV($390M) has a higher market cap than MGX($62.4M). VERV YTD gains are higher at: -25.000 vs. MGX (-53.740). MGX has higher annual earnings (EBITDA): -65.06M vs. VERV (-221.91M). VERV has more cash in the bank: 524M vs. MGX (275M). MGX has less debt than VERV: MGX (46.1M) vs VERV (70M). MGX has higher revenues than VERV: MGX (55.1M) vs VERV (32.3M).
MGXVERVMGX / VERV
Capitalization62.4M390M16%
EBITDA-65.06M-221.91M29%
Gain YTD-53.740-25.000215%
P/E RatioN/AN/A-
Revenue55.1M32.3M171%
Total Cash275M524M52%
Total Debt46.1M70M66%
TECHNICAL ANALYSIS
Technical Analysis
MGXVERV
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MISEX34.68N/A
N/A
Midas Special Opportunities
SREQX12.81N/A
N/A
PGIM Select Real Estate R6
DQICX30.03N/A
N/A
BNY Mellon Equity Income Fund C
FAAIX28.14N/A
N/A
Fidelity Advisor Asset Manager 70% I
IHSRX21.19N/A
N/A
Hartford Small Company R3

MGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGX has been loosely correlated with KOD. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if MGX jumps, then KOD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGX
1D Price
Change %
MGX100%
+1.21%
KOD - MGX
41%
Loosely correlated
+0.28%
CVM - MGX
39%
Loosely correlated
-45.45%
VERV - MGX
38%
Loosely correlated
N/A
KYTX - MGX
35%
Loosely correlated
N/A
IMNM - MGX
34%
Loosely correlated
+6.82%
More

VERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, VERV has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VERV jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VERV
1D Price
Change %
VERV100%
N/A
BEAM - VERV
58%
Loosely correlated
N/A
CRSP - VERV
55%
Loosely correlated
+1.46%
RXRX - VERV
51%
Loosely correlated
N/A
XNCR - VERV
50%
Loosely correlated
+2.26%
ARWR - VERV
50%
Loosely correlated
N/A
More